Table 2.

Distribution of selected characteristics of Caucasian population-based prostate cancer cases used for SLCO2B1 and SLCO1B3 SNP genotype analyses

Total cases1,309
Age, y
 40–49102 (7.8)
 50–54189 (14.4)
 55–59325 (24.8)
 60–64395 (30.2)
 65–69153 (11.7)
 70–74145 (11.1)
Family history of prostate cancera
 Negative1,026 (78.4)
 Positive283 (21.6)
PSA tests within 5 y prior to diagnosis
 None288 (22.1)
 1–2320 (24.5)
 3+638 (48.7)
 Unknown63 (4.8)
BMI (weight/height2)
 <25.0429 (32.8)
 25.0–29.9638 (48.7)
 ≥30.0242 (18.5)
Smoking status
 Never523 (40.0)
 Former631 (48.2)
 Current155 (11.8)
Diagnostic PSA, ng/mL
 0.0–3.9178 (13.6)
 4.0–9.9722 (55.2)
 10.0–19.9191 (14.6)
 ≥20118 (9.0)
 Missing100 (7.6)
Gleason score
 2–6, 3 + 41103 (84.5)
 4 + 3, 8–10202 (15.5)
Tumor stage
 Local1,023 (78.2)
 Regional254 (19.4)
 Distant32 (2.4)
Treatment
 RP770 (58.8)
 XRT ± hormones359 (27.4)
 AD61 (4.7)
 Other4 (0.3)
 Watchful waiting115 (8.8)
  • aFirst-degree family history of prostate cancer.